Jiangsu Hengrui Medicine Co., Ltd.

This phase 3 trial compares a new drug, SHR-A1811, to the standard treatment T-DM1 in women with HER2-positive breast cancer who still have cancer cells after initial therapy. The goal is to see if SHR-A1811 can better prevent the cancer from coming back. Participants receive eit…

This study tests a new medicine called SHR-3167 in adults with type 2 diabetes whose blood sugar is not well controlled by pills. About 100 participants will receive different dosing plans to see which works best at lowering blood sugar while avoiding dangerously low sugar levels…

This early-stage study tests a new drug called HRS-3738 in people with two types of blood cancer—non-Hodgkin's lymphoma and multiple myeloma—that have returned or not improved after prior treatments. The main goals are to find a safe dose and check how well the drug works. About …

This phase 3 trial tests a new drug called SHR-A1811, given alone or with pertuzumab, against the standard treatment (trastuzumab, pertuzumab, and docetaxel) in 868 women with HER2-positive breast cancer that has returned or spread. The goal is to see if the new approach can dela…

This early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This phase 2 trial tests a gel called SHR0302Base in 155 adults with stable nonsegmental vitiligo. The goal is to see if it can improve skin color on the face and neck by at least 50%. Participants are randomly assigned to get the real gel or a placebo, and neither they nor their…

This phase 3 trial tests whether combining two drugs—camrelizumab (an immunotherapy) and rivoceranib (a targeted therapy)—can prevent liver cancer from coming back in patients at high risk of recurrence after curative surgery or ablation. About 687 participants will receive eithe…

This phase 3 trial tests whether adding two drugs (camrelizumab and rivoceranib) to a standard liver cancer procedure (TACE) helps people with incurable liver cancer live longer without their disease getting worse. About 423 participants are randomly assigned to get either the co…

This study tests a new drug (HR070803) added to standard chemotherapy and a targeted therapy for people with advanced colorectal cancer that has spread and cannot be removed by surgery. About 669 participants will receive either the new combo or standard treatment. The goal is to…

This study tests a new medication, SHR-3167, against a standard long-acting insulin (insulin degludec) in people with type 2 diabetes who already use basal insulin. The goal is to see which one controls blood sugar better and is safer. About 173 adults aged 18-65 with type 2 diab…

This early-phase study tests a new drug called HRS-4642 combined with several other anti-cancer medicines in 47 adults with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check safety, find the best dose, and see if the combination can shrink…

This Phase 3 trial tests whether a combination of two drugs, camrelizumab and famitinib, works better than standard chemotherapy for women with recurrent or metastatic cervical cancer. About 443 participants will be randomly assigned to receive either the drug combo or chemo. The…

This early-stage trial tests a new drug called HRS-4642 in 102 adults with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check the drug's safety, find the best dose, and see early signs of tumor shrinkage. Participants must have tried other …

This early-stage study tracks a single injection of [14C]HRS-9190 in 6 healthy men to see how it is absorbed, broken down, and eliminated. The goal is to understand the drug's metabolism and excretion, not to treat any disease. Participants are closely monitored for side effects,…